Policlinico San Marco, Bergamo, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
Obes Surg. 2024 Nov;34(11):4220-4227. doi: 10.1007/s11695-024-07522-9. Epub 2024 Oct 7.
Laparoscopic BariClip gastroplasty (LBCG) is a new reversible bariatric procedure designed to replicate the restrictive effects of laparoscopic sleeve gastrectomy (LSG) by placing a clip vertically on the stomach. This technique achieves gastric lumen restriction without the need for resection, ensuring organ preservation and reversibility. However, concerns have arisen regarding potential complications such as gastroesophageal reflux disease (GERD), slippage, or erosion of the stomach. The aim of the study is to evaluate the outcomes and complications of LBCG.
This is a monocentric retrospective study. We analyzed 149 patients who underwent LBCG procedure between July 2021 and November 2023. A minimum follow-up period of 6 months was observed for all patients, recording clinically relevant GERD through GERD-Q score questionnaires. Weight loss was monitored through body mass index (BMI) and % total weight loss (%TWL), registered during follow-up visits.
Overall, 149 patients were eligible for this study. Overall complication rate was 8% (12/149). The average BMI went from 40 ± 4.37 kg/m to 28 ± 4.29 kg/m (p < 0.05) in 6 months, while the mean %TWL was 22.6% after at least 6 months of follow-up. Clinically relevant GERD went from 18.1% (27/149) to 10.7% (16/149), p = 0.1262. As expected, also the PPI usage was not altered significantly (17.8% vs 16.4%), p = 0.8714.
LBCG remains an experimental procedure that must be approached with caution. Nonetheless, the potential of LBCG to reproduce the effects of LSG while reducing GERD makes it a promising new reversible option for the treatment of morbid obesity.
腹腔镜 BariClip 胃成形术（LBCG）是一种新的可逆减肥手术，旨在通过在胃上垂直放置夹子来复制腹腔镜袖状胃切除术（LSG）的限制效果。这种技术通过不进行切除来实现胃腔限制，从而确保器官的保留和可逆转性。然而，人们对潜在的并发症（如胃食管反流病[GERD]、胃滑脱或胃侵蚀）表示担忧。本研究旨在评估 LBCG 的结果和并发症。
这是一项单中心回顾性研究。我们分析了 2021 年 7 月至 2023 年 11 月期间接受 LBCG 手术的 149 名患者。所有患者的随访时间均至少为 6 个月，通过 GERD-Q 评分问卷记录有临床意义的 GERD。通过 BMI 和 %总体重减轻（%TWL）监测体重减轻，在随访期间进行登记。
总体而言，149 名患者符合本研究条件。总并发症发生率为 8%（12/149）。6 个月时，平均 BMI 从 40±4.37kg/m 降至 28±4.29kg/m（p<0.05），至少 6 个月随访时的平均 %TWL 为 22.6%。有临床意义的 GERD 从 18.1%（27/149）降至 10.7%（16/149），p=0.1262。如预期的那样，质子泵抑制剂（PPI）的使用也没有明显变化（17.8%比 16.4%，p=0.8714）。
LBCG 仍然是一种需要谨慎对待的实验性手术。尽管如此，LBCG 具有复制 LSG 效果的潜力，同时减少 GERD，使其成为治疗病态肥胖症的一种有前途的新可逆选择。
